Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1172 ARTÍCULOS , VIENDO DEL 286 AL 300

Glycerophospholipids and glycerophospholipid-derived lipid mediators: a complex meshwork in Alzheimer's disease pathology

Frisardi V, Panza F, Seripa D, Farooqui T, Farooqui AA.

Prog Lipid Res. 2011 Oct;50(4):313-30. doi: 10.1016/j.plipres.2011.06.001. Epub 2011 Jun 15.

Age- and disease-related neuroplasticity of chemically identified neuronal circuits: a tribute to Professor Erminio Costa

Armstrong D.

Pharmacol Res. 2011 Oct;64(4):336-8. doi: 10.1016/j.phrs.2011.05.023. Epub 2011 Jun 16.

Modes of Aβ toxicity in Alzheimer's disease

Götz J, Eckert A, Matamales M, Ittner LM, Liu X.

Cell Mol Life Sci. 2011 Oct;68(20):3359-75. doi: 10.1007/s00018-011-0750-2. Epub 2011 Jun 25.

In silico design and search for acetylcholinesterase inhibitors in Alzheimer's disease with a suitable pharmacokinetic profile and low toxicity

da Silva VB, de Andrade P, Kawano DF, Morais PA, de Almeida JR, Carvalho I, Taft CA, da Silva CH.

Future Med Chem. 2011 Jun;3(8):947-60. doi: 10.4155/fmc.11.67.

Effects of galantamine in Alzheimer's disease: double-blind withdrawal studies evaluating sustained versus interrupted treatment

Gaudig M, Richarz U, Han J, Van Baelen B, Schäuble B.

Curr Alzheimer Res. 2011 Nov;8(7):771-80. doi: 10.2174/156720511797633205.

Further evidence for vascular mediation of Alzheimer's dementia pathogenesis?

Breitner JC.

Biol Psychiatry. 2011 Jul 15;70(2):113-4. doi: 10.1016/j.biopsych.2011.05.026.

Rivastigmine transdermal patch: a review of its use in the management of dementia of the Alzheimer's type

Dhillon S.

Drugs. 2011 Jun 18;71(9):1209-31. doi: 10.2165/11206380-000000000-00000.

The recent updates of therapeutic approaches against aβ for the treatment of Alzheimer's disease

Ling S, Zhou J, Rudd JA, Hu Z, Fang M.

Anat Rec (Hoboken). 2011 Aug;294(8):1307-18. doi: 10.1002/ar.21425. Epub 2011 Jun 29.

Nuclear receptors as therapeutic targets for Alzheimer's disease

Mandrekar-Colucci S, Landreth GE.

Expert Opin Ther Targets. 2011 Sep;15(9):1085-97. doi: 10.1517/14728222.2011.594043. Epub 2011 Jul 1.

New insights into the roles of megalin/LRP2 and the regulation of its functional expression

Marzolo MP, Farfán P.

Biol Res. 2011;44(1):89-105. doi: 10.4067/S0716-97602011000100012. Epub 2011 May 11.

Combination therapy for Alzheimer's disease

Patel L, Grossberg GT.

Drugs Aging. 2011 Jul 1;28(7):539-46. doi: 10.2165/11591860-000000000-00000.

Membrane and surface interactions of Alzheimer's Aβ peptide--insights into the mechanism of cytotoxicity

Williams TL, Serpell LC.

FEBS J. 2011 Oct;278(20):3905-17. doi: 10.1111/j.1742-4658.2011.08228.x. Epub 2011 Jul 26.

Magnetic resonance imaging-measured atrophy and its relationship to cognitive functioning in vascular dementia and Alzheimer's disease patients

Logue MW, Posner H, Green RC, Moline M, Cupples LA, Lunetta KL, Zou H, Hurt SW, Farrer LA, Decarli C; MIRAGE Study Group.

Alzheimers Dement. 2011 Sep;7(5):493-500. doi: 10.1016/j.jalz.2011.01.004. Epub 2011 Jul 1.

Design considerations for characterizing psychiatric trajectories across the lifespan: application to effects of APOE-ε4 on cerebral cortical thickness in Alzheimer's disease

Thompson WK, Hallmayer J, O'Hara R; Alzheimer's Disease Neuroimaging Initiative.

Am J Psychiatry. 2011 Sep;168(9):894-903. doi: 10.1176/appi.ajp.2011.10111690. Epub 2011 Jul 1.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias